PATENT CLAIM ANALYSIS

Application Number: 15958358
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "252130"]

Abstract:
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

Claim (Index 55):
A method of treating an ocular condition in a subject in need thereof, the method comprising topically administering to an eye of the subject a unit dosage form, wherein the unit dosage form comprises:\n a therapeutically-effective amount of a Tie-2 activator, a cyclodextrin; and an aqueous vehicle; wherein the unit dosage form is formulated as a drop for topical administration to the eye of the subject; wherein the unit dosage form comprises from about 0.1 mg/mL to about 100 mg/mL of the Tie-2 activator; wherein the therapeutically-effective amount is from about 0.1 mg to about 100 mg; wherein a plasma concentration in the subject of the Tie-2 activator is:\n a) for administration of a dose of about 5 mg, not less than about 1 ng/mL at about 0.25 hours after the administration; not less than about 1 ng/mL at about 1 hour after the administration; not less than about 1 ng/mL at about 2 hours after the administration; and about 0 ng/mL to about 30 ng/mL at about 4 hours after the administration; \n b) for administration of a dose of about 15 mg, not less than about 1 ng/mL at about 0.25 hours after the administration; not less than about 1 ng/mL at about 1 hour after the administration; not less than about 1 ng/mL at about 2 hours after the administration; and about 0 ng/mL to about 40 ng/mL at about 4 hours after the administration; \n c) for administration of a dose of about 22.5 mg, not less than about 1 ng/mL at about 0.25 hours after the administration; not less than about 1 ng/mL at about 1 hour after the administration; not less than about 1 ng/mL at about 2 hours after the administration; and not less than about 1 ng/mL at about 4 hours after the administration; or \n d) for administration of a dose of about 30 mg, not less than about 1 ng/mL at about 0.25 hours after the administration; not less than about 1 ng/mL at about 1 hour after the administration; not less than about 1 ng/mL at about 2 hours after the administration; and not less than about 1 ng/mL at about 4 hours after the administration.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 91.0
- Lexical Diversity: 1.51515
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13999670', '15355910', '13724396', '15016599', '15705639']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7199967465293713
- 35 USC 102 Novelty (BERT): 0.5333899928178284
- Combined Prediction Score: 0.7013360711582171
- Mean Citation Score: 259.09862000000004
- Max Citation Score: 364.1654
- Similarity Product: 268.4999230894923

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test